{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:09:50Z","timestamp":1778494190910,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s12325-012-0007-y","type":"journal-article","created":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T07:51:56Z","timestamp":1331538716000},"page":"234-248","source":"Crossref","is-referenced-by-count":46,"title":["Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis"],"prefix":"10.1007","volume":"29","author":[{"given":"Machaon M. K.","family":"Bonafede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Princic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,9]]},"reference":[{"key":"7_CR1","unstructured":"Enbrel\u00ae (etanercept) [Prescribing Information]. lmmunex Corporation, Thousand Oaks, CA."},{"key":"7_CR2","unstructured":"Humira\u00ae (adalimumab) [Prescribing Information]. Abbott Laboratories, Abbott Park, IL."},{"key":"7_CR3","unstructured":"Remicade\u00ae (infliximab) [Prescribing Information]. Centocor, Inc., Malvern, PA."},{"key":"7_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1185\/030079908X261177","volume":"24","author":"A. Hochberg","year":"2008","unstructured":"Hochberg A, Johnston S, John A. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin. 2008;24:469\u2013480.","journal-title":"Curr Med Res Opin"},{"key":"7_CR5","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"R.G.B. Langley","year":"2005","unstructured":"Langley RGB, Krueger GG, Griffiths A. Psoriasis: epidemiology, clinical features, and quality of life. Rheum Dis. 2005;64:ii18\u2013ii23.","journal-title":"Rheum Dis"},{"key":"7_CR6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A. Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851\u2013864.","journal-title":"J Am Acad Dermatol"},{"key":"7_CR7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/kem348","volume":"47","author":"P. Sidiropoulos","year":"2008","unstructured":"Sidiropoulos P, Hatemi G, Song I, et al. Evidencebased recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practicing rheumatologists. Rheumatology. 2008;47:355\u2013361.","journal-title":"Rheumatology"},{"key":"7_CR8","volume-title":"Rheumatoid Arthritis","author":"L. Moreland","year":"2008","unstructured":"Moreland L. Rheumatoid Arthritis, 2nd ed. London: Remedica Publishing LTD, 2008.","edition":"2nd ed."},{"key":"7_CR9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/1529-0131(199904)42:3<415::AID-ANR4>3.0.CO;2-Z","volume":"42","author":"S.E. Gabriel","year":"1999","unstructured":"Gabriel SE, Crowson CS, O\u2019Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955\u20131985. Arthritis Rheum. 1999;42:415\u2013420.","journal-title":"Arthritis Rheum"},{"key":"7_CR10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MAJ.0b013e31820f8c99","volume":"341","author":"J. Reveille","year":"2011","unstructured":"Reveille J. Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011;341:284\u2013286.","journal-title":"Am J Med Sci"},{"key":"7_CR11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/acr.20211","volume":"62","author":"M. Blom","year":"2010","unstructured":"Blom M, Kievit W, Kuper H, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice Arthritis Care Res. 2010;62:1335\u20131341.","journal-title":"Arthritis Care Res"},{"key":"7_CR12","first-page":"iii","volume":"10","author":"Y.F. Chen","year":"2006","unstructured":"Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10:iii\u2013iv, xi\u2013xiii, 1\u2013229.","journal-title":"Health Technol Assess"},{"key":"7_CR13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"G.M. Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert C, Nurmohamed M, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long- term follow-up. JAMA. 2011;305:1460\u20131468.","journal-title":"JAMA"},{"key":"7_CR14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D. Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445\u20131452.","journal-title":"Rheumatology"},{"key":"7_CR15","first-page":"26","volume":"29","author":"R.J. Moots","year":"2011","unstructured":"Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose escalation, nonbiologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Expert Rheumatol. 2011;29:26\u201334.","journal-title":"Clin Expert Rheumatol"},{"key":"7_CR16","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/ard.2005.038349","volume":"65","author":"L. Klareskog","year":"2006","unstructured":"Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other diseasemodifying antirheumatic drugs. Ann Rheum Dis. 2006;65:1578\u20131584.","journal-title":"Ann Rheum Dis"},{"key":"7_CR17","first-page":"99","volume":"109","author":"C.A. Foerder","year":"2002","unstructured":"Foerder CA, Rogge MC. Enbrel (etanercept). Dev Biol (Basel). 2002;109:99\u2013102.","journal-title":"Dev Biol (Basel)"},{"key":"7_CR18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1185\/03007995.2010.483127","volume":"26","author":"X. Huang","year":"2010","unstructured":"Huang X, Gu N, Fox K, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. CMRO. 2010;26:1637\u20131645.","journal-title":"CMRO"},{"key":"7_CR19","first-page":"1281","volume":"67","author":"D. Harrison","year":"2010","unstructured":"Harrison D, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. AJSP. 2010;67:1281\u20131287.","journal-title":"AJSP"},{"key":"7_CR20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.clinthera.2009.04.002","volume":"31","author":"D. Ollendorf","year":"2009","unstructured":"Ollendorf D, Kingman D, Hazard R, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31:821\u2013835.","journal-title":"Clin Ther"},{"key":"7_CR21","first-page":"351","volume":"2","author":"N. Gu","year":"2010","unstructured":"Gu N, Huang X, Fox K, et al. Claims data analysis of dosing and cost of TNF antagonists in rheumatoid arthritis. Am J Pharm Benefits. 2010;2:351\u2013359.","journal-title":"Am J Pharm Benefits"},{"key":"7_CR22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0149-2918(05)00090-1","volume":"27","author":"D. Weycker","year":"2005","unstructured":"Weycker D. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or = 65 years with rheumatoid arthritis. Clin Ther. 2005;27:646\u2013656.","journal-title":"Clin Ther"},{"key":"7_CR23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1185\/030079907X210615","volume":"23","author":"E. Wu","year":"2007","unstructured":"Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin. 2007;23:1749\u20131759.","journal-title":"Curr Med Res Opin"},{"key":"7_CR24","unstructured":"First Databank, Inc. Wholesale Acquisition Costs (WAC). Available at: www.firstdatabank.com . Accessed Sept 14, 2011."},{"key":"7_CR25","doi-asserted-by":"crossref","unstructured":"Schabert V, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2011. [Epub ahead of print].","DOI":"10.3111\/13696998.2011.644645"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-012-0007-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0007-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T01:24:13Z","timestamp":1561425853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-012-0007-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1007\/s12325-012-0007-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}